Histogenics (HSGX) Reaches $2.70 After 4.00% Down Move; 18 Analysts Covering Analog Devices, Inc. (ADI)

January 16, 2018 - By Darrin Black

The stock of Histogenics Corporation (NASDAQ:HSGX) is a huge mover today! The stock decreased 2.88% or $0.08 during the last trading session, reaching $2.7. About 133,515 shares traded or 9.54% up from the average. Histogenics Corporation (NASDAQ:HSGX) has declined 7.61% since January 16, 2017 and is downtrending. It has underperformed by 24.31% the S&P500.The move comes after 7 months negative chart setup for the $64.99 million company. It was reported on Jan, 16 by Barchart.com. We have $2.59 PT which if reached, will make NASDAQ:HSGX worth $2.60 million less.

Among 30 analysts covering Analog Devices (NASDAQ:ADI), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Analog Devices had 112 analyst reports since July 22, 2015 according to SRatingsIntel. Oppenheimer downgraded Analog Devices, Inc. (NASDAQ:ADI) on Tuesday, December 15 to “Perform” rating. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, August 19. The stock of Analog Devices, Inc. (NASDAQ:ADI) has “Buy” rating given on Monday, January 18 by Stifel Nicolaus. The firm has “Outperform” rating given on Tuesday, April 19 by Raymond James. Oppenheimer maintained Analog Devices, Inc. (NASDAQ:ADI) on Friday, November 17 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Buy” on Sunday, August 27. The stock of Analog Devices, Inc. (NASDAQ:ADI) earned “Buy” rating by Oppenheimer on Wednesday, May 31. The firm earned “Buy” rating on Wednesday, September 30 by Citigroup. The stock of Analog Devices, Inc. (NASDAQ:ADI) earned “Buy” rating by Evercore on Monday, September 14. Nomura upgraded Analog Devices, Inc. (NASDAQ:ADI) on Friday, January 15 to “Neutral” rating. See Analog Devices, Inc. (NASDAQ:ADI) latest ratings:

03/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $100.0 Maintain
29/12/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $100.0 Maintain
19/12/2017 Broker: PiperJaffray Rating: Neutral New Target: $92 Initiates Coverage On
13/12/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $103 New Target: $108 Maintain
21/11/2017 Broker: SunTrust Rating: Buy New Target: $112.0 Maintain
21/11/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $107.0 Maintain
21/11/2017 Broker: BMO Capital Markets Rating: Buy New Target: $100.0 Maintain
22/11/2017 Broker: Morgan Stanley Rating: Buy New Target: $103.0 Maintain
22/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $100.0 Maintain
21/11/2017 Broker: Drexel Hamilton Rating: Buy New Target: $105.0 Maintain

The stock increased 1.19% or $1.0917 during the last trading session, reaching $93.1117. About 1.60 million shares traded. Analog Devices, Inc. (NASDAQ:ADI) has risen 45.85% since January 16, 2017 and is uptrending. It has outperformed by 29.15% the S&P500.

Since August 21, 2017, it had 0 buys, and 19 sales for $16.07 million activity. 4,000 shares were sold by Henderson Gregory N., worth $366,080. 10,000 shares valued at $911,300 were sold by STATA RAY on Wednesday, January 3. $640,640 worth of Analog Devices, Inc. (NASDAQ:ADI) was sold by SEIF MARGARET K on Friday, January 5. CHAMPY JAMES sold $1.13M worth of stock or 12,500 shares. 4,505 shares were sold by Real Peter, worth $376,258. On Friday, September 1 the insider Hassett Joseph sold $944,824. The insider NOVICH NEIL S sold $785,759.

Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.07, from 1.14 in 2017Q2. It improved, as 45 investors sold Analog Devices, Inc. shares while 232 reduced holdings. 100 funds opened positions while 234 raised stakes. 315.41 million shares or 0.53% more from 313.75 million shares in 2017Q2 were reported. Archford Strategies Ltd Liability Corp accumulated 4,451 shares. Emerald Advisers Pa invested 0.05% in Analog Devices, Inc. (NASDAQ:ADI). Washington Savings Bank holds 0.03% of its portfolio in Analog Devices, Inc. (NASDAQ:ADI) for 2,455 shares. Sigma Planning holds 0.02% in Analog Devices, Inc. (NASDAQ:ADI) or 2,922 shares. First Trust L P holds 0.26% of its portfolio in Analog Devices, Inc. (NASDAQ:ADI) for 1.19 million shares. 57,400 were accumulated by Amf Pensionsforsakring Ab. Citadel Lc owns 4.57M shares. Commerzbank Aktiengesellschaft Fi owns 7,099 shares. Brookmont has 2.21% invested in Analog Devices, Inc. (NASDAQ:ADI) for 46,898 shares. Cambridge Research Advsr Incorporated has 0.02% invested in Analog Devices, Inc. (NASDAQ:ADI) for 21,444 shares. Central Natl Bank & holds 1.24% of its portfolio in Analog Devices, Inc. (NASDAQ:ADI) for 57,924 shares. State Of Alaska Department Of Revenue owns 29,502 shares or 0.13% of their US portfolio. Puzo Michael J stated it has 44,219 shares. Illinois-based Zacks Investment Mngmt has invested 0.04% in Analog Devices, Inc. (NASDAQ:ADI). Jaffetilchin Invest Prtn Ltd Liability Co reported 0.06% of its portfolio in Analog Devices, Inc. (NASDAQ:ADI).

Analog Devices, Inc. designs, manufactures, and markets a portfolio of solutions that leverage analog, mixed-signal, and digital signal processing technology, including integrated circuits , algorithms, software, and subsystems. The company has market cap of $34.32 billion. It offers data converter products, which translate real-world analog signals into digital data, as well as translates digital data into analog signals; high-performance amplifiers to condition analog signals; and radio frequency ICs to support cellular infrastructure. It has a 44.98 P/E ratio. The firm also provides MEMS technology solutions, including accelerometers used to sense acceleration, gyroscopes to sense rotation, and inertial measurement units to sense multiple degrees of freedom.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $64.99 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp had 16 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright with “Buy” on Monday, December 19. The stock of Histogenics Corporation (NASDAQ:HSGX) earned “Market Perform” rating by William Blair on Wednesday, September 7. The rating was maintained by Needham with “Buy” on Monday, September 19. The stock of Histogenics Corporation (NASDAQ:HSGX) earned “Neutral” rating by BTIG Research on Friday, November 13. As per Friday, August 12, the company rating was upgraded by BTIG Research. As per Thursday, December 21, the company rating was maintained by Canaccord Genuity. The stock of Histogenics Corporation (NASDAQ:HSGX) earned “Buy” rating by H.C. Wainwright on Thursday, November 2. The stock has “Buy” rating by Needham on Friday, November 13. H.C. Wainwright maintained it with “Buy” rating and $3.5 target in Wednesday, December 27 report. Zacks downgraded the stock to “Hold” rating in Thursday, August 27 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts